Weekly Intelligence · 7 articles
Vet Industry Intel: May 3 – May 9, 2026
High-signal veterinary industry stories triangulated from multiple sources, scored for relevance, and grouped by event type.
Funding & Investment
FDA announcing funding for grants in veterinary innovation - Vet Candy
The FDA has announced funding availability for grants dedicated to veterinary innovation, aiming to support advancements in animal health.
FDA · Vet Candy
Regulatory & Policy
FDA clears first drug for both noise aversion and separation anxiety in dogs - Veterinary Practice News
The FDA has cleared the first drug approved to treat both noise aversion and separation anxiety in dogs.
FDA · Veterinary Practice News
IV-delivered therapy for canine OA advances toward FDA approval - Veterinary Practice News
An intravenous therapy for canine osteoarthritis has advanced toward FDA approval, marking a significant regulatory development in veterinary pharmaceuticals.
FDA · Veterinary Practice News
FDA adds ointment to its emergency use arsenal against screwworm - American Veterinary Medical Association
The FDA has added an ointment to its emergency use authorization arsenal to combat screwworm, as reported by the American Veterinary Medical Association.
FDA · American Veterinary Medical Association
Products & Technology
FDA approves first drug for both noise aversion and separation anxiety in dogs - DVM360
The FDA has approved the first pharmaceutical drug indicated for treating both noise aversion and separation anxiety in dogs.
FDA · DVM360
Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility - PR Newswire
Gallant announced promising pilot data for its IV-delivered stem cell therapy for canine osteoarthritis alongside progress in the FDA conditional approval pathway.
Gallant · FDA · PR Newswire
Industry News
Zoetis (ZTS) Is Down 24.1% After Cutting 2026 Guidance On Softer U.S. Pet Demand – Has The Bull Case Changed? - Yahoo Finance
Zoetis shares fell 24.1% after the company cut its 2026 financial guidance due to softer U.S. pet demand.
Zoetis · Yahoo Finance